JP2012504651A - Toll様受容体の活性を抑制するための方法 - Google Patents
Toll様受容体の活性を抑制するための方法 Download PDFInfo
- Publication number
- JP2012504651A JP2012504651A JP2011530268A JP2011530268A JP2012504651A JP 2012504651 A JP2012504651 A JP 2012504651A JP 2011530268 A JP2011530268 A JP 2011530268A JP 2011530268 A JP2011530268 A JP 2011530268A JP 2012504651 A JP2012504651 A JP 2012504651A
- Authority
- JP
- Japan
- Prior art keywords
- tlr3
- agent
- disease
- patient
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
Abstract
Description
TLR3Δ64を初代細胞で発現させる。
TLR3Δ64はTLR3活性のシグナル伝達及び調節を欠損している。
TLRΔ64の輸送の欠損
TLR3Δ64の細胞表面発現、TLR3Δ64の細胞内局在、及びTLR3Δ64タンパク質の可溶性を研究して、TLR3Δ64による野生型TLR3活性の抑制メカニズムを評価した。HEK293T細胞で過剰発現したタンパク質のFACS解析により、TLR3Δ64及びTLR3の細胞表面発現を研究した。細胞表面上に部分的に局在している野生型TLR3(図3A)に反して、TLR3Δ64はHEK293T細胞表面では検出されなかった(図3B)。しかしながら、どちらのタンパク質も細胞内に存在した(図3D、3E)。TLR3シグナル伝達に必要とされるC−末端シグナル伝達ドメインを欠き、NF−κB活性の誘導の欠損を示すTLR3変異体(TLR3ΔTIR)を、本実験において更なる対照として用いた(Matsumoto et al.,Biochem.Biophys.Res.Commun.293:1364〜1369,2002)。TIRシグナル伝達ドメインの欠乏と、下流のシグナル伝達の活性化の不能にも関わらず、TLR3ΔTIRは細胞表面と細胞内の両方に見出された(図3C、3F)。したがって、活性の欠如はTLR3の正しい局在を予測するものではない。
TLR3Δ64はRNA結合領域に干渉しなかった。
Claims (31)
- Toll様受容体3(TLR3)の活性の抑制を必要としている患者において、前記活性を抑制するための方法であって、TLR3の移動に干渉する剤を前記患者に投与することを含む、方法。
- 前記剤がTLR3変異体である、請求項1に記載の方法。
- 前記TLR3変異体が、配列番号1に示すアミノ酸配列を有するポリペプチドを含む、請求項2に記載の方法。
- 前記TLR3変異体が、配列番号2に示すアミノ酸配列を有するポリペプチドを含む、請求項2に記載の方法。
- 前記剤が、配列番号3に示すアミノ酸配列を有するポリペプチドを含む、請求項1に記載の方法。
- 前記患者がヒトである、請求項1に記載の方法。
- 前記剤が、モノクローナル抗体、抗体断片、代替の足場物質又はタンパク質と結合している、請求項1に記載の方法。
- 前記剤を、TLR3活性に関する第2の調節因子と組み合わせて投与することを更に含む、請求項1に記載の方法。
- 前記第2の調節因子が抗体、MIMETIBODY(商標)コンストラクト、又はオリゴヌクレオチドであるか、又はTLR3の低分子量アンタゴニストである、請求項8に記載の方法。
- 前記剤が、TLR3の細胞表面発現に干渉する、請求項1に記載の方法。
- 前記剤が、小胞体からのTLR3の移動に干渉する、請求項1に記載の方法。
- 前記剤が、エンドソームへのTLR3の移動に干渉する、請求項1に記載の方法。
- 前記剤が、TLR3とそのリガンドとの共局在に干渉する、請求項1に記載の方法。
- 炎症状態を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記炎症状態を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記炎症状態が感染に付随するものである、請求項14に記載の方法。
- 前記炎症状態が、膵臓炎、円形脱毛症、アトピー性皮膚炎、自己免疫性肝炎、ベーチェット病、肝硬変、肝繊維症、クローン病、限局性腸炎、炎症性白斑、多発性硬化症、天疱瘡/類天疱瘡、原発性胆汁性肝硬変、乾癬、強皮症、硬化性胆管炎、全身性紅斑性狼瘡、ループス腎炎、中毒性表皮壊死症、潰瘍性大腸炎、いぼ、肥厚性瘢痕、ケロイド、又はアセトアミノフェン誘発性障害である、請求項14に記載の方法。
- 壊死性疾患を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記壊死性疾患を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記壊死性疾患が急性腎不全である、請求項17に記載の方法。
- 感染症を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、感染症を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記感染症が、炭疽病、クロストリジウム・ディフィシレ感染、脳炎/髄膜炎、心内膜炎、C型肝炎、インフルエンザ/重症急性呼吸器症候群(SARS)、肺炎、敗血症、火傷性又は外傷性皮膚適応症、又は全身性炎症反応症(SIRS)である、請求項19に記載の方法。
- 心血管疾患を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記心血管疾患を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記心臓血管疾患が、動脈硬化、心筋梗塞又は脳卒中である、請求項21に記載の方法。
- I型又はII型糖尿病を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記I型又はII型糖尿病を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 癌を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記癌を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記癌が、急性白血病、乳癌、慢性白血病、結腸直腸癌、食道癌、胃癌、ホジキン病、肺癌、リンパ腫、黒色腫、多発性骨髄腫、非ホジキン病、子宮癌、膵臓癌、前立腺癌、非上皮性悪性腫瘍、腎細胞癌、頭頸部癌、又はウイルス誘発性癌である、請求項24に記載の方法。
- リウマチ様疾患を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記リウマチ様疾患を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記リウマチ性疾患が、自己免疫性甲状腺炎、自己免疫性血管炎、円板状紅斑性狼瘡、ループス腎炎、変形性関節症、多発性軟骨炎、リウマチ性多発筋痛症、乾癬性関節炎、関節リウマチ、全身性紅斑性狼瘡、又は全身性強皮症である、請求項26に記載の方法。
- 肺疾患を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記肺疾患を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記肺疾患が、急性肺障害、急性呼吸窮迫症候群、急性喘息増悪、急性COPD増悪、特発性肺繊維症、又は類肉腫である、請求項28に記載の方法。
- 神経疾患を治療又は予防する方法であって、治療上の有効量の剤を前記剤を必要としている患者に投与することを含み、前記剤は、前記神経疾患を治療又は予防するのに十分な時間にわたってTLR3の移動に干渉する、方法。
- 前記神経疾患が、脳卒中、アルツハイマー型認知症、髄膜炎、脊髄障害、外傷、脱髄疾患、又は痛みである、請求項30に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10203308P | 2008-10-02 | 2008-10-02 | |
US61/102,033 | 2008-10-02 | ||
PCT/US2009/059383 WO2010040054A2 (en) | 2008-10-02 | 2009-10-02 | Methods for suppressing toll-like receptor activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012504651A true JP2012504651A (ja) | 2012-02-23 |
JP2012504651A5 JP2012504651A5 (ja) | 2012-09-20 |
Family
ID=42074235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011530268A Pending JP2012504651A (ja) | 2008-10-02 | 2009-10-02 | Toll様受容体の活性を抑制するための方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8895263B2 (ja) |
EP (1) | EP2344175B1 (ja) |
JP (1) | JP2012504651A (ja) |
CA (1) | CA2739083C (ja) |
ES (1) | ES2550264T3 (ja) |
WO (1) | WO2010040054A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019176901A1 (ja) * | 2018-03-12 | 2019-09-19 | 学校法人日本医科大学 | microRNA-21を標的とした変形性関節症による疼痛の緩和 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
PE20110808A1 (es) * | 2008-10-31 | 2011-10-31 | Janssen Biotech Inc | Anticuerpos contra el receptor 3 de tipo toll |
CN104159610A (zh) * | 2011-09-12 | 2014-11-19 | 詹森生物科技公司 | 用于治疗代谢和心血管疾病的3型toll样受体拮抗剂 |
AU2014228886B2 (en) * | 2013-03-15 | 2018-11-29 | University Of Florida Research Foundation | Compounds for treating neurodegenerative proteinopathies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124676A1 (en) * | 2005-05-17 | 2006-11-23 | The Interthyr Corporation | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors |
WO2007051201A2 (en) * | 2005-10-28 | 2007-05-03 | Centocor, Inc. | Tlr3 glycosylation site muteins and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001332A2 (en) | 2004-08-04 | 2007-01-04 | University Of Massachusetts | Anti-pathogen immunoadhesins |
TWI487535B (zh) * | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體3(toll like receptor3)拮抗劑,方法及用途 |
US7705199B2 (en) | 2005-03-02 | 2010-04-27 | The Scripps Research Institute | Compositions and methods for treatment of autoimmune and related diseases |
US7700728B2 (en) * | 2005-03-24 | 2010-04-20 | Schering Corporation | Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors |
US20070211752A1 (en) * | 2006-03-13 | 2007-09-13 | Utstarcom, Incorporated | Method of establishing a PPP session over an air interface |
US8066981B2 (en) * | 2006-11-14 | 2011-11-29 | The Texas A & M University System | Compositions and methods related to toll-like receptor-3 |
-
2009
- 2009-10-02 CA CA2739083A patent/CA2739083C/en active Active
- 2009-10-02 US US12/572,338 patent/US8895263B2/en active Active
- 2009-10-02 EP EP09818568.9A patent/EP2344175B1/en active Active
- 2009-10-02 WO PCT/US2009/059383 patent/WO2010040054A2/en active Application Filing
- 2009-10-02 JP JP2011530268A patent/JP2012504651A/ja active Pending
- 2009-10-02 ES ES09818568.9T patent/ES2550264T3/es active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124676A1 (en) * | 2005-05-17 | 2006-11-23 | The Interthyr Corporation | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors |
WO2007051201A2 (en) * | 2005-10-28 | 2007-05-03 | Centocor, Inc. | Tlr3 glycosylation site muteins and methods of use |
Non-Patent Citations (4)
Title |
---|
MOLECULAR IMMUNOLOGY, vol. 44, JPN6013053688, 2007, pages 3633 - 3640, ISSN: 0002667703 * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, JPN6013053689, 2007, pages 17696 - 17705, ISSN: 0002667704 * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, JPN6013053690, 2007, pages 7668 - 7678, ISSN: 0002667705 * |
YONSEI MEDICAL JOURNAL, vol. 45, JPN6013053691, 2004, pages 359 - 361, ISSN: 0002667706 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019176901A1 (ja) * | 2018-03-12 | 2019-09-19 | 学校法人日本医科大学 | microRNA-21を標的とした変形性関節症による疼痛の緩和 |
JPWO2019176901A1 (ja) * | 2018-03-12 | 2020-12-17 | 学校法人日本医科大学 | microRNA−21を標的とした変形性関節症による疼痛の緩和 |
JP7016184B2 (ja) | 2018-03-12 | 2022-02-21 | 学校法人日本医科大学 | microRNA-21を標的とした変形性関節症による疼痛の緩和 |
Also Published As
Publication number | Publication date |
---|---|
CA2739083C (en) | 2018-05-01 |
US20100092462A1 (en) | 2010-04-15 |
US8895263B2 (en) | 2014-11-25 |
EP2344175A2 (en) | 2011-07-20 |
WO2010040054A3 (en) | 2010-06-17 |
EP2344175A4 (en) | 2012-05-02 |
ES2550264T3 (es) | 2015-11-05 |
CA2739083A1 (en) | 2010-04-08 |
WO2010040054A2 (en) | 2010-04-08 |
EP2344175B1 (en) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10981981B2 (en) | Compositions and methods for growth factor modulation | |
CA2566607C (en) | Use of lacritin in promoting ocular cell survival | |
US20170073406A1 (en) | Compositions and methods for growth factor modulation | |
Hu et al. | Netrin-4 promotes glioblastoma cell proliferation through integrin β4 signaling | |
US9333257B2 (en) | FGFR1 antibodies and treatment of cancer | |
Khankan et al. | Regulation of Fibronectin-EDA through CTGF Domain–Specific Interactions with TGFβ2 and Its Receptor TGFβRII | |
Zanotti et al. | Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-β1 treatment | |
JP2012504651A (ja) | Toll様受容体の活性を抑制するための方法 | |
Rathor et al. | Src-mediated caveolin-1 phosphorylation regulates intestinal epithelial restitution by altering Ca2+ influx after wounding | |
US20110034383A1 (en) | Cxcl12 gamma a chemokine and uses thereof | |
KR20200017421A (ko) | 항-trkb 항체 | |
WO2018050852A2 (en) | Binding agents for use in therapy | |
CN113227143A (zh) | 抗c-Met激动剂抗体及其应用 | |
KR20200069839A (ko) | 항 c-Met 아고니스트 항체 및 이의 용도 | |
RU2788083C2 (ru) | Пептид для лечения возрастной макулярной дегенерации | |
Sciandra et al. | First molecular characterization and immunolocalization of keratoepithelin in adult human skeletal muscle | |
Zolfaghari | Investigations on regulation, signaling properties and functions of CCN5 | |
WO2011105527A1 (ja) | 神経成長促進剤 | |
Mony | Regulation of the Na, K-ATPase beta1 subunit during TGF-beta2-mediated epithelial to mesenchymal transition in human retinal pigmented epithelial cells | |
KR20240016346A (ko) | 루미노코커스 토크스로부터 유래된 펩티드 | |
JP2023552919A (ja) | Wnt受容体rykに対する抗体バリアント | |
Ulmansky et al. | Antibodies to Laminin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140407 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140414 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140702 |